AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A pharmaceutical composition comprising, separately or together, an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β_2 adrenoreceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts for simultaneous, sequential or separate administration by inhalation in the treatment of asthma bronchiale ~~airway disorders~~ in mammals.

2. (Previously Presented) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) formoterol.

3. (Previously Presented) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) salmeterol.

4. (Previously Presented) The pharmaceutical composition according to claim 1, comprising (i) loteprednol or loteprednol etabonate and (ii) reproterol.

5. – 6. (Canceled)

7. (Currently Amended) A method for the treatment of asthma bronchiale ~~allergies and/or airway disorders~~, comprising administering to a patient in need of such treatment an efficacious amount of (i) loteprednol or loteprednol etabonate and (ii) at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts, if appropriate together with pharmaceutically acceptable excipients or vehicles, for simultaneous, sequential or separate administration.

8. (Currently Amended) A process for the preparation of a pharmaceutical composition for the treatment of asthma bronchiale ~~allergies and/or airway disorders~~, comprising an effective amount of the active compound loteprednol or loteprednol etabonate and at least one β_2 adrenoceptor agonist selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol, and pharmaceutically tolerable salts, wherein loteprednol or loteprednol etabonate and the β_2 adrenoceptor agonist or the β_2 adrenoceptor agonists are mixed individually or together, if appropriate together with pharmaceutically acceptable excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.